Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

What You Need to Know Ahead of AbbVie’s Earnings Release

With a market cap of $384.6 billion, AbbVie Inc. (ABBV) is a global research-driven pharmaceutical company that develops and markets advanced therapies across immunology, oncology, neuroscience, and aesthetics. The Illinois-based company is known for blockbuster drugs like Humira and newer growth drivers such as Skyrizi and Rinvoq. 

The drug giant is expected to announce its fiscal first-quarter earnings for 2026 on Friday, Apr. 24, before the market opens. Ahead of the event, analysts expect ABBV to report a profit of $3.01 per share on a diluted basis, up 22.4% from $2.46 per share in the year-ago quarter. The company has consistently...

Fundamentals

See More
  • Market Capitalization, $K 380,120,960
  • Shares Outstanding, K 1,768,169
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,075 M
  • EBITDA $ 24,061 M
  • 60-Month Beta 0.38
  • Price/Sales 6.29
  • Price/Cash Flow 14.36
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 33.46% (+2.27%)
  • Historical Volatility 26.12%
  • IV Percentile 93%
  • IV Rank 45.71%
  • IV High 51.27% on 04/08/25
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 8) 6.50 (3.11%)
  • Put/Call Vol Ratio 1.06
  • Today's Volume 10,911
  • Volume Avg (30-Day) 12,483
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 232,863
  • Open Int (30-Day) 231,183
  • Expected Range 202.59 to 215.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $3.01
  • Number of Estimates 10
  • High Estimate $3.17
  • Low Estimate $2.97
  • Prior Year $2.46
  • Growth Rate Est. (year over year) +22.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
201.80 +3.71%
on 03/24/26
237.11 -11.73%
on 03/04/26
-24.97 (-10.66%)
since 03/02/26
3-Month
201.80 +3.71%
on 03/24/26
237.11 -11.73%
on 03/04/26
-20.02 (-8.73%)
since 01/02/26
52-Week
164.39 +27.31%
on 04/09/25
244.81 -14.51%
on 10/01/25
+4.10 (+2.00%)
since 04/02/25

Most Recent Stories

More News
What You Need to Know Ahead of AbbVie’s Earnings Release

AbbVie will release its first-quarter earnings this month, and analysts anticipate a double-digit bottom-line growth.

XLV : 146.60 (-0.76%)
$SPX : 6,569.27 (-0.09%)
ABBV : 208.81 (-2.87%)
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

IRVINE, Calif. , March 31, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced its fourth annual CoolMonth, featuring exclusive offers on CoolSculpting ® , the...

ABBV : 208.81 (-2.87%)
AbbVie to Host First-Quarter 2026 Earnings Conference Call

NORTH CHICAGO, Ill. , March 31, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2026 financial results on Wednesday, April 29, 2026, before the market opens. AbbVie will...

ABBV : 208.81 (-2.87%)
Merck Just Made a Big Bet on a New Cancer Growth Engine

Merck's $6.7 billion Terns acquisition bolsters its oncology pipeline while reinforcing its strong margins, steadily growing dividend, and long-term growth.

MRK : 120.20 (-0.53%)
LLY : 935.94 (-1.95%)
ABBV : 208.81 (-2.87%)
Allergan Aesthetics Releases Findings on the Safety and Efficacy of Repeat TrenibotE Treatments and Data on Medical Weight Loss Aesthetics Patient Behaviors at the 2026 American Academy of Dermatology Meeting (AAD)

- Poster presentation highlights investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid onset and a consistently favorable safety profile across studied patient populations

ABBV : 208.81 (-2.87%)
AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

NORTH CHICAGO, Ill. , March 27, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new research across its dermatology portfolio to be presented at the 2026 American Academy of Dermatology...

ABBV : 208.81 (-2.87%)
Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)

- Five scientific e-posters highlight investigational neurotoxin trenibotulinumtoxinE (TrenibotE), demonstrating rapid improvement in glabellar lines (as early as 8 hours), robust and consistent efficacy,...

ABBV : 208.81 (-2.87%)
Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco

NORTH CHICAGO, Ill. , March 26, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, a global leader in medical aesthetics treatments and manufacturers of the market-leading JUVÉDERM ®...

ABBV : 208.81 (-2.87%)
Want Income and Growth? This Simple 3-ETF Portfolio Does Both

In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.

MO : 65.73 (+0.38%)
AAPL : 255.43 (-0.08%)
AVGO : 313.79 (+0.10%)
CVX : 198.70 (+0.65%)
VZ : 49.40 (+0.02%)
$SPX : 6,569.27 (-0.09%)
JPM : 294.50 (-0.30%)
JNJ : 242.99 (-0.46%)
SCHD : 30.51 (-0.02%)
ABBV : 208.81 (-2.87%)
BMY : 59.40 (-2.78%)
MSFT : 371.41 (+0.55%)
Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Global data from over 12,000 consumers signals the future of modern aesthetics will be multimodal treatment plans and holistic, natural results

ABBV : 208.81 (-2.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 225.74
2nd Resistance Point 223.09
1st Resistance Point 219.04
Last Price 208.81
1st Support Level 212.34
2nd Support Level 209.69
3rd Support Level 205.64

See More

52-Week High 244.81
Fibonacci 61.8% 214.09
Last Price 208.81
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.